This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetics - Cmax
Timeframe: Up to 6 hours after IMP administration
Pharmacokinetics - Tmax
Timeframe: Up to 6 hours after IMP administration
Pharmacokinetics - AUC
Timeframe: Up to 6 hours after IMP administration